Human Reproductive Technologies Market | Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• HUMAN REPRODUCTIVE TECHNOLOGIES MARKET ANALYSIS
• Human Reproductive Technologies Market, By
  Technology (Infertility Drugs, Contraceptive
  Drugs and Devices), and By Region (North America,
  Latin America, Europe, Asia Pacific, Middle East
  Africa) - Size, Share, Outlook, and Opportunity
  Analysis, 2020 - 2027

3

• Human reproductive technologies include, Assisted
  Reproductive Technology (ART), prognostics,
  contraception, and same-sex procreation. ART aids
  in the treatment of low fertility or infertility
  using artificial insemination, artificial
  reproduction, cloning, cytoplasmic transfer,
  fertility medication, hormone treatment, and
  others.
• The global human reproductive technologies market
  is estimated to account for US 28,426.7 Mn in
  2019 in terms of value and US 34,228.3 Mn by the
  end of 2027
• Global Human Reproductive Technologies Market
  Drivers
• Increasing prevalence of maternal mortality is
  expected to propel growth of the global human
  reproductive technologies market over the
  forecast period. For instance, according to
  Maternal Mortality 1990 to 2015 Estimates by
  WHO, UNICEF, UNFPA, World Bank Group and the
  United Nations Population Division, Sub-Saharan
  Africa recorded the highest ratio or maternal
  mortality, at 555 per 100, 000 live births, from
  1990 to 2015. Moreover, the United Nations is
  focused on achieving the Sustainable Development
  Goals 2015 - 2030 global maternal mortality ratio
  target of less than 70 per 100 000 live births.
• Moreover, decreasing birth rate is also expected
  to aid in growth of the market. For instance,
  according to National Vital Statistics System,
  the provisional number of births for the U.S. in
  2018 was 3,788,235, registering a decrease of 2
  from 2017 and the lowest number of births in 32
  years.

4

• Figure 1. Global Human Reproductive Technologies
  Market Share (), by Value, by Region, 2019

5

• Global Human Reproductive Technologies Market
  Restraints
• Limited insurance coverage for ART is expected to
  hinder growth of the market. ART is a relatively
  new and yet to be fully proven process in many
  countries. Such a status causes insurance
  companies to be apprehensive about covering
  expenses. For instance, in Canada, there is
  limited fund for IVF and intracytoplasmic sperm
  injection and hence infertile couples have to
  bear the cost of treatment. The average cost for
  infertility treatment in Canada is quite
  expensive and ranges from between US 10,000 to
  US 20,000.
• Moreover, infertility treatments may not prove to
  be conclusive or effective and thereby need to be
  repeated sometimes. Such a risk of repetition of
  procedures negatively affects the decision of the
  consumers and limits market growth

6
Human Reproductive Technologies Market Report
Coverage

7
Global Human Reproductive Technologies Market
Opportunities

• Increasing rate of literacy is expected to offer
  lucrative growth opportunities for players in the
  global human reproductive technologies market.
  For instance, according to United Nations
  Children's Fund, globally, the youth literacy
  rate increased from 83 to 91 during 1985-2018.
• Moreover, RD in male birth control pill is also
  expected to aid in growth of the market. For
  instance, in March 2018, researchers from the
  University of Washington presented positive
  results from a small clinical trial of 100 men
  for a male birth control pill that inhibits
  testosterone production.
• The global human reproductive technologies market
  was valued at US 28,426.7 Mn in 2019 and is
  forecast to reach a value of US 34,228.3 Mn by
  2027 at a CAGR of 2.4 between 2020 and 2027.

8
Figure 2. Global Human Reproductive Technologies
Market Value (US Bn), and Y-o-Y Growth (),
2019-2027

9

• Market Trends/Key Takeaways
• Increasing population is expected to propel
  demand for emergency human reproductive
  technologies. For instance, according to
  projections by Population Reference Bureau (PRB)
  included in the 2018 World Population Data Sheet,
  the world population is expected to reach 9.9
  billion by 2050, up 2.3 billion or 29 from an
  estimated 7.6 billion people in 2018.
• However, low adoption of emergency human
  reproductive technologies in emerging economies
  is expected to act as a drag for the demand. For
  instance, according to PRBs 2019 Family Planning
  Data Sheet, fewer than 15 of married women of
  reproductive age use a modern human reproductive
  technologies in Democratic Republic of the Congo.
  

10
Global Human Reproductive Technologies Market
Competitive Landscape

• Major players operating in the global human
  reproductive technologies include, Abbott
  Laboratories, Evofem Biosciences, Inc., Actavis
  Generics (Teva Pharmaceutical Industries Ltd.),
  Sun Pharmaceutical Industries Ltd., Perrigo
  Company plc, Uniprix, Gavis Pharmaceuticals
  (Lupin Limited), Sandoz International GmbH,
  Aurobindo Pharma Limited, HRA Pharma, SA, Mankind
  Pharma, Cryos USA, Merck Co, Bayer HealthCare
  AG, Church Dwight, Co. Inc., Allergan, Pfizer,
  Inc., Agile Therapeutics Inc., BioSante
  Pharmaceuticals Inc., Mayer Laboratories, Inc.,
  Pantarhei Bioscience B.V., Cook Medical, Inc.,
  Ferring Pharmaceuticals, Johnson Johnson, Daré
  Bioscience, Inc., and Merck Serono.

11
Global Human Reproductive Technologies Market
Key Developments

• Major players in the market are focused on
  approval and launch of new products to expand
  their product portfolio. For instance, in May
  2020, Evofem Biosciences, Inc. received the U.S.
  Food and Drug Administration (FDA) approval for
  Phexxi (lactic acid, citric acid and potassium
  bitartrate) vaginal gel used to prevent pregnancy
  in females of reproductive potential for use as
  an on-demand method of contraception.
• Major players in the market are also focused on
  adopting partnership strategies to expand their
  product portfolio. For instance, in May 2020,
  Daré Bioscience, Inc., a developer of womens
  health solutions partnered with Health Decisions,
  Inc., a full-service contract research
  organization (CRO) specializing in womens health
  clinical research and diagnostic development,
  under which Health Decisions will exclusively
  provide CRO services within the U.S. to support
  RD of Darés pipeline of contraception,
  fertility, and gynecological disorders products.

12

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/human-reproductive-technologies-mar
  ket-3921

13
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

14
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

15
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/